ENTAEnanta Pharmaceuticals Inc
ENTA
Enanta Pharmaceuticals Inc1,154
Mkt Cap
$402.15MVolume
45,530.0052W High
$17.1552W Low
$5.55PE Ratio
-5.33ENTA Fundamentals
Price
$14.27Prev Close
$13.83Open
$13.7250D MA
$13.60Beta
1.07Avg. Volume
118,774.85EPS (Annual)
-$3.84P/B
3.45Rev/Employee
$544,366.67$267.58
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial...
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Monday
Enanta Pharmaceuticals (NASDAQ:ENTA) will be releasing its Q2 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-enanta-pharmaceuticals-inc-stock...
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven ha...
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving Average - Here's Why
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Above 50 Day Moving Average - Should You Sell...
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the...
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data...
<
1
2
...
>
Compact View
Not available
Not available